Business Context and Reporting Period
This Form 8-K was filed by Tharimmune, Inc. (not Canton Strategic Holdings, Inc.) on December 5, 2024. The registrant is a Delaware corporation trading on The Nasdaq Stock Market under the symbol "THAR" and is classified as an emerging growth company. The filing reports the entry into a material definitive agreement for a private placement of securities.
Key Financial Metrics
The filing details a capital raise rather than operational financial results. Key metrics include:
- Gross Proceeds: Approximately $2.02 million expected from the private placement.
- Securities Issued: 470,289 shares of Common Stock, 491,157 Pre-Funded Warrants, and 480,721 Common Warrants.
- Purchase Price: $2.1010 per share of Common Stock (or equivalent).
- Warrant Terms: Common Warrants have an exercise price of $2.0310, are exercisable after six months, and have a 5.5-year term. Pre-Funded Warrants are exercisable immediately at $0.001 per share.
- Ownership Limit: Holders are restricted from exercising warrants if it results in ownership exceeding 4.99% (or 9.99% at election) of outstanding common stock.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement with institutional investors on December 5, 2024. This represents a significant capital infusion event distinct from prior periods, with closing expected on December 9, 2024, subject to customary conditions.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use net proceeds for clinical development and working capital, specifically supporting its TH104 development program.
Management Commentary: President Street Global served as the exclusive placement agent. The Company issued a press release on December 6, 2024, to announce the transaction.
Risks and Contingencies: The closing is contingent upon the satisfaction of customary closing conditions. The filing notes that the descriptions of the agreement terms are qualified by the full text of the exhibits attached.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $2.02 million gross proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Confirm the exact net proceeds after deducting placement agent fees and offering expenses.
- Monitor the progress of the TH104 development program as the designated use of funds.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants or Common Warrants.